文献速递妇科

卵巢癌免疫检查点抑制剂治疗中血清CA-125监测的效用

Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.
PubMed 文献 · Gynecol Oncol · 2020-06-02

研究比较临床获益组(RECIST 1.1评估完全缓解、部分缓解或疾病稳定且持续时间≥24周)与无临床获益组的CA-125变化百分比。结果显示,两组CA-125升高比例无显著差异(73% vs 82%,p=0.48),但治疗开始12周内CA-125平均升高幅度在两组间有显著差异(34% vs 195%,p=0.008)。结论提示应谨慎使用早期CA-125数据指导治疗决策。

要点

  • ICI治疗中临床获益与无获益患者CA-125升高比例相似(73% vs 82%)。
  • 治疗12周内CA-125平均升高幅度在获益组显著低于无获益组(34% vs 195%)。
  • 早期CA-125变化不宜单独用于指导EOC患者的ICI治疗决策。

核心结论

  • ICI治疗前12周内CA-125升高幅度在临床获益与无获益患者间有统计学显著差异,但两组CA-125升高的可能性相同,应谨慎解读早期CA-125数据。

主要发现

  • 临床获益组15例中11例(73%)CA-125从基线至治疗结束升高,无临床获益组44例中36例(82%)升高(p=0.48)。
  • 治疗开始12周内CA-125平均升高百分比在临床获益组为34%,无临床获益组为195%(p=0.008)。

关键数值与推荐

  • 临床获益定义为RECIST 1.1评估的完全缓解、部分缓解或疾病稳定且持续时间≥24周。
  • 组间比较采用Wilcoxon秩和检验。

临床怎么用

  • 医生在使用早期CA-125数据指导上皮性卵巢癌患者ICI治疗决策时应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to evaluate the utility of serum cancer antigen-125 (CA-125) levels to monitor patients with epithelial ovarian cancer (EOC) undergoing immune checkpoint inhibitor (ICI) therapy. METHOD: This was a single-center retrospective review of all patients with EOC who were treated with ICI therapy from January 2013 to May 2017. This study compared the percentage change in baseline CA-125 in patients who had clinical benefit, defined as complete response, partial response, or stable disease by RECIST 1.1, with duration ≥24 weeks, versus those who did not. The groups were compared by Wilcoxon rank-sum test. RESULTS: Fifty-nine (66%) of 89 patients who underwent ICI therapy had CA-125 data at baseline and during treatment. Of those who derived clinical benefit, 11/15 (73%) experienced an increase in CA-125 from baseline to end of treatment. Of those who did not derive clinical benefit, 36/44 (82%) experienced a CA-125 increase (p = 0.48). The average % increase from baseline to within 12 weeks of treatment initiation for patients with and without clinical benefit was 34% and 195%, respectively (p = 0.008). CONCLUSION: Our analysis demonstrates a statistically significant difference in the magnitude of increase in CA-125 levels within the first 12 weeks of treatment between patients who achieved clinical benefit and those who did not. However, both groups of patients were equally likely to experience an increase in CA-125 within 12 weeks. These findings suggest that physicians should apply caution when using early CA-125 data to guide treatment decisions for patients with EOC undergoing ICI therapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Boland JL, Zhou Q, Iasonos AE, et al. Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. Gynecol Oncol. 2020. PMID: 32507515. doi:10.1016/j.ygyno.2020.04.710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。